Bayer and NextRNA Therapeutics enter strategic collaboration to develop small molecules targeting long non-coding RNAs (lncRNAs) in oncology
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
Pfizer launches PfizerForAll™, a digital platform that helps simplify access to healthcare
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Pfizer and BioNTech provide update on mRNA-based combination vaccine program against influenza and COVID-19 in individuals 18-64 years of age
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Pfizer announces top-line results of ABRYSVO® for RSV in immunocompromised adults
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan)
- Details
- Category: Novartis
![Novartis Novartis](/images/logo/novartis.png)
Vividion Therapeutics to expand with new global research and development center
- Details
- Category: Bayer
![Bayer Bayer](/images/logo/bayer.png)
Pfizer announces positive topline results From Phase 3 study of hemophilia A gene therapy candidate
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/logo/pfizer.png)
The AFFINE study achieved its primary objective of non-inferiority, as well as superiority, of total annualized bleeding rate (ABR) from Week 12 through at least 15 months of follow up post-infusion compared with routine Factor VIII (FVIII) replacement prophylaxis treatment.
More Pharma News ...
- Darolutamide meets primary endpoint in Phase III ARANOTE trial
- Pfizer advances development of once-daily formulation of oral GLP-1 receptor agonist danuglipron
- AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson's disease
- GSK and CureVac to restructure collaboration into new licensing agreement
- Sipavibart EMA regulatory submission accepted under accelerated assessment for COVID-19 prevention
- Berlin Center for Gene and Cell Therapies kicked off in Berlin
- Bayer receives Breakthrough Therapy designation in China for BAY 2927088